ECSP17078433A - Composiciones de ácido obeticólico y métodos de uso - Google Patents

Composiciones de ácido obeticólico y métodos de uso

Info

Publication number
ECSP17078433A
ECSP17078433A ECIEPI201778433A ECPI201778433A ECSP17078433A EC SP17078433 A ECSP17078433 A EC SP17078433A EC IEPI201778433 A ECIEPI201778433 A EC IEPI201778433A EC PI201778433 A ECPI201778433 A EC PI201778433A EC SP17078433 A ECSP17078433 A EC SP17078433A
Authority
EC
Ecuador
Prior art keywords
methods
acid compositions
obeticolic acid
obeticolic
dissolution
Prior art date
Application number
ECIEPI201778433A
Other languages
English (en)
Inventor
Richard G Lancaster
Mitsuhiro Matono
Masashi Kagihiro
Jeffrey Edwards
Cathi Sciacca
Tonya Marmon
Ikuko Taoka
Leigh A Macconell
Mark Pruzanski
Lise Eliot
Richard Pencek
Roya Hooshmand-Rad
David Shapiro
Kay K Olmstead
Original Assignee
Intercept Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17078433(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd filed Critical Intercept Pharmaceuticals Inc
Publication of ECSP17078433A publication Critical patent/ECSP17078433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación se refiere a formulaciones de ácido obeticólico con estabilidad, disolución y/o solubilidad mejoradas, a métodos para preparar las mismas para su uso y a métodos para tratar diversas enfermedades y afecciones.
ECIEPI201778433A 2015-04-27 2017-11-24 Composiciones de ácido obeticólico y métodos de uso ECSP17078433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
ECSP17078433A true ECSP17078433A (es) 2018-02-28

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201778433A ECSP17078433A (es) 2015-04-27 2017-11-24 Composiciones de ácido obeticólico y métodos de uso

Country Status (25)

Country Link
US (8) US10052337B2 (es)
EP (3) EP4371616A2 (es)
JP (2) JP6941057B2 (es)
KR (1) KR20170140325A (es)
CN (1) CN107531742A (es)
AU (2) AU2016255045B2 (es)
BR (1) BR112017023161A2 (es)
CA (1) CA2983609C (es)
CL (1) CL2017002727A1 (es)
CO (1) CO2017011535A2 (es)
CR (1) CR20170492A (es)
EA (1) EA201792354A1 (es)
EC (1) ECSP17078433A (es)
IL (2) IL294575A (es)
MA (1) MA41999A (es)
MX (1) MX2017013805A (es)
NI (1) NI201700128A (es)
PE (1) PE20180690A1 (es)
PH (1) PH12017501956A1 (es)
SG (2) SG10202003110PA (es)
SV (1) SV2017005555A (es)
TN (1) TN2017000452A1 (es)
TW (1) TWI723017B (es)
WO (1) WO2016176208A1 (es)
ZA (1) ZA201707981B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
AU2017244982A1 (en) * 2016-03-31 2018-11-01 Intercept Pharmaceuticals, Inc. Film-coated tablet having high chemical stability of active ingredient
JP6968821B2 (ja) * 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
JP2019519592A (ja) * 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用
CN117229994A (zh) * 2016-11-04 2023-12-15 儿童医院医学中心 肝类器官疾病模型以及其制备和使用方法
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
CN111050772A (zh) * 2017-07-24 2020-04-21 英特塞普特医药品公司 同位素标记的胆汁酸衍生物
WO2019106043A1 (en) * 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
WO2020097167A1 (en) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Methods of using obeticholic acid
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
AU2020247991A1 (en) * 2019-03-26 2021-10-21 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
WO2020198576A1 (en) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Methods of modulating regulatory t cells
US20230114753A1 (en) * 2020-03-06 2023-04-13 Mili Healthcare Trade Dmcc, Limited Liability Company Use of a group of markers for diagnosing and adjusting treatment of primary biliary cholangitis, pharmaceutical composition and solid dosage form for treating primary biliary cholangitis
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
WO2022076683A1 (en) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Methods of treating coronaviral infection with obeticholic acid
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2023181077A1 (en) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Stable liquid composition comprising obeticholic acid or salts thereof
WO2023205447A2 (en) * 2022-04-21 2023-10-26 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024043842A1 (en) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
WO2024104960A1 (en) 2022-11-15 2024-05-23 Synthon B.V. Stable formulation comprising obeticholic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
JP4021327B2 (ja) * 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
CN100350977C (zh) 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
US20050101565A1 (en) 2002-07-03 2005-05-12 Esperion Therapeutics, Inc. Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1922150A1 (en) 2005-07-07 2008-05-21 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
RU2011139643A (ru) * 2009-03-17 2013-04-27 Акскан Фарма, Инк. Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
MX344838B (es) * 2009-04-24 2017-01-09 Iceutica Pty Ltd Metodo para la produccion de polvos de nanoparticulas y microparticulas comerciales.
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
CN104781272A (zh) * 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
CN105592846A (zh) 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
DK2997035T3 (en) 2013-05-14 2018-07-02 Intercept Pharmaceuticals Inc 11-HYDROXY-6-SUBSTITUTED BALIC ACID DERIVATIVES AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS
AU2014320463B2 (en) * 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
NI201700128A (es) 2018-04-11
SG11201708606VA (en) 2017-11-29
MA41999A (fr) 2018-03-07
EA201792354A1 (ru) 2018-03-30
JP2018514534A (ja) 2018-06-07
TW201703773A (zh) 2017-02-01
WO2016176208A1 (en) 2016-11-03
EP3288958A1 (en) 2018-03-07
US20200171053A1 (en) 2020-06-04
MX2017013805A (es) 2018-09-06
IL294575A (en) 2022-09-01
CR20170492A (es) 2018-05-15
TWI723017B (zh) 2021-04-01
US10052337B2 (en) 2018-08-21
ZA201707981B (en) 2019-03-27
US20200046735A1 (en) 2020-02-13
PH12017501956A1 (en) 2018-03-26
CA2983609A1 (en) 2016-11-03
JP2021183651A (ja) 2021-12-02
US10646499B2 (en) 2020-05-12
CO2017011535A2 (es) 2018-01-31
AU2016255045A1 (en) 2017-11-09
IL255269A (en) 2018-02-28
AU2016255045B2 (en) 2020-04-16
EP3971199A1 (en) 2022-03-23
CL2017002727A1 (es) 2018-04-27
US10751349B2 (en) 2020-08-25
IL255269B (en) 2022-08-01
US20200046736A1 (en) 2020-02-13
TN2017000452A1 (en) 2019-04-12
US20190255071A1 (en) 2019-08-22
US10758549B2 (en) 2020-09-01
CA2983609C (en) 2024-05-07
JP6941057B2 (ja) 2021-09-29
KR20170140325A (ko) 2017-12-20
US20200054650A1 (en) 2020-02-20
SG10202003110PA (en) 2020-05-28
CN107531742A (zh) 2018-01-02
PE20180690A1 (es) 2018-04-23
AU2020205315A1 (en) 2020-08-06
EP4371616A2 (en) 2024-05-22
SV2017005555A (es) 2019-01-18
US20220133745A1 (en) 2022-05-05
US20190076446A1 (en) 2019-03-14
EP3288958A4 (en) 2018-09-26
US20170035784A1 (en) 2017-02-09
BR112017023161A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
EA201691582A1 (ru) Новые фармацевтические препараты
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
BR112016020181A2 (pt) Composições de ácido lipoico éster colina e métodos de uso.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
CO2019008110A2 (es) Activador de nrf2
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CL2017000663A1 (es) Uso de compuestos heterocíclicos fluoroalquenil sulfano para repeler moluscos
EA201892157A1 (ru) Фосфаплатиновые жидкие составы